Cytochrome P450 and other families of drug metabolizing enzymes are commonly thought of and studied for their ability to metabolize xenobiotics and other foreign entities as they are eliminated from the body. Equally as important, however, is the homeostatic role that many of these enzymes play in maintaining the proper levels of endogenous signaling molecules such as lipids, steroids, and eicosanoids, as well as their ability to modulate protein-protein interactions involved in downstream signaling cascades. Throughout the years, many of these endogenous ligands or protein partners of drug metabolizing enzymes have been associated with a wide range of disease states from cancer to various cardiovascular, neurological or inflammatory diseases, prompting an interest in whether or not modulation of drug metabolizing enzyme activity could have a subsequent pharmacological impact or lessening of disease severity. Beyond direct regulation of endogenous pathways, drug metabolizing enzymes have also been proactively targeted for their ability to activate pro-drugs with subsequent pharmacological activity or enhance the efficacy of a co-administered drug by inhibiting the metabolism of that drug through a rationally designed drug-drug interaction (i.e., ritonavir and HIV antiretroviral therapy). The focus of this minireview will be to highlight research aimed at characterizing cytochrome P450 and other drug metabolizing enzymes as therapeutic targets.Examples of successfully marketed drugs as well as early research efforts will be discussed. Finally, emerging areas of research utilizing typical drug metabolizing enzymes to impact clinical outcomes will be discussed.